Mountain States Genetics Regional Collaborative Center's Metabolic Newborn Screening Long-Term Follow-Up Study: A collaborative multi-site approach to newborn screening outcomes research

Genetics in Medicine

Volumn 12, Issue 12 SUPPL, 2010, Pages

  Wright, Erica L ^a,b   Van Hove, Johan L K ^a   Thomas, Janet ^a  

^a University of Colorado Denver and Children s Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

disease specific care plans; Mountain States Genetics Regional Collaborative Center's Metabolic Consortium; newborn screening follow up shared datasets; newborn screening long term follow up; newborn screening outcome measures

Indexed keywords

ARTICLE; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL RESEARCH; METABOLIC DISORDER; NEWBORN SCREENING; OUTCOME ASSESSMENT;

EID: 78650790874     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181fe5d50     Document Type: Article

References (33)

1. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylk-etonuria in large populations of newborn infants. Pediatrics 1963;32:338-343.
2. Sahai I, Marsden D. Newborn screening. Crit Rev Clin Lab Sci 2009;46: 55-82.
3. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: phenylke-tonuria: screening and management, October 16-18, 2000. Pediatrics, 2001; 108, 972-982.
4. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method of acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. L Inherit Metab Dis 1990;13:321-324.
5. ACMG Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system- executive summary. Pediatrics 2006; 117:S296-S307.
6. The National Newborn Screening and Genetics Resource Center. Available at: http://genes-r-us.uthscsa.edu. Accessed August 1, 2007.
7. Botkin JR. Research for newborn screening: developing a national framework. Pediatrics 2005;116:862-871.
8. Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child 1999;80:459-462.
9. Dionisi-Vici C, Deodato F, Röschinger W, Rhead W, Wilcken B. 'Classical' organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis 2006;29:383-389.
10. James PM, Levy HL. The clinical aspects of newborn screening: importance of newborn screening follow-up. Ment Retard Dev Disabil Res Rev 2006; 12:246-254.
11. Hoff T, Hoyt A. Practices and perceptions of long-term follow-up among state newborn screening programs. Pediatrics 2006;117:1922-1929. (Pubitemid 46071235)
12. Association of Maternal and Child Health Programs. Newborn screening long-term follow-up assessment. AMCHP report, 2007. Available at: http:// www.amchp.org. Accessed August 1, 2007.
13. Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome and implications. Pediatrics 2003;111:1399-1406.
14. Waisbren SE, Albers S, Amato S, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003;290:2564-2572.
15. Waisbren SE. Newborn screening for metabolic disorders. JAMA 2006;296: 993-995.
16. The Mountain States Genetics Regional Collaborative Center. Available at: http://www.msgrcc.org. Accessed August 1, 2007.
17. American College of Medical Genetics. Available at: http://www.acmg.net/ resources/policies/ACT/condition-analytelinks.htm. Accessed August 1, 2007.
18. Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res 2005; 57:78R-86R.
19. Welsh MC, Pennington BF, Ozonoff S, Rouse B, McCabe ER. Neuropsy-chology of early-treated phenylketonuria: specific executive function deficits. Child Dev 1990;61:1697-1713.
20. Wilcken B, Haas M, Joy P, et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 2007;369:37-42.
21. Kölker S, Garbade SF, Greenberg CR, et al. Natural history, outcome, and treatment efficacy in children and adults with gluatryl-CoA dehydrogenase deficiency. Pediatric Res 2006;59:840-847.
22. Komrower GM, Sardharwalla IB, Coutts JM, Ingham D. Management of maternal phenylketonuria: an emerging clinical problem. Br Med J 1979;1: 1383-1387.
23. Straussberg R, Strauss AW. A novel mutation of late-onset very-long-chain acyl-CoA dehydrogenase deficiency. Pediatr Neurol 2002;27:136-137.
24. Ensenauer R, Vockley J, Willard JM, et al. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet 2004;75:1136-1142.
25. Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet 2006;142C: 95-103.
26. Van Maldegem BT, Duran M, Wanders RJ, et al. Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency. JAMA 2006;296:943-952.
27. Wilcken B. Recent advances in newborn screening. J Inherit Metab Dis 2007;30:129-133.
28. Liebl, B, Nennstiel-Ratzel U, Roscher A, von Kries R. Data required for the evaluation of newborn screening programmes. Eur J Pediatr 2003;162:S57-S61.
29. Bodamer OA, Hoffmann GF, Lindner M. Expanded newborn screening in Europe 2007. J Inherit Metab Dis 2007;30:439-444.
30. Arnold GL, Koeberl DD, Matern D, et al. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 2008;93:363-370.
31. Arnold GL, Van Hove J, Freedenberg D, et al. A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 2009;96:85-90.
32. Howell RR, Engelson G. Structures for clinical follow-up: newborn screening. J Inherit Metab Dis 2007;30:600-605.
33. Camfield CS, Joseph M, Hurley T, Campbell K, Sanderson S, Camfield PR. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J Pediatr 2004;145:53-57.